Medicare beneficiaries who rely on Part D prescription drug coverage will face a higher out-of-pocket spending limit in 2027. The Centers for Medicare and Medicaid Services set the annual threshold at $2,400 for that year, a $300 jump from the $2,100 cap in effect for 2026. The increase follows an automatic annual adjustment built into the Inflation Reduction Act’s redesign of Part D, which first capped costs at $2,000 in 2025. For seniors on fixed incomes, each yearly bump raises a direct question: how quickly will the rising cap erode the savings the redesign was supposed to lock in?
Why the $300 jump from 2026 to 2027 hits differently
When Congress wrote the IRA’s Part D overhaul, it anchored the out-of-pocket cap at $2,000 for 2025 and tied future years to an Annual Percentage Increase, or API. That mechanism raised the cap to $2,100 for 2026, and CMS has now confirmed a further increase to $2,400 for 2027. In just two years, the ceiling has climbed $400 above the original statutory floor, a 20 percent rise from the baseline.
The practical effect is straightforward. Once a beneficiary’s out-of-pocket spending on covered Part D drugs reaches the annual threshold, that person pays nothing for covered prescriptions for the rest of the calendar year. A higher threshold means more dollars spent before that protection activates. Beneficiaries taking expensive brand-name medications or specialty drugs could reach the cap within the first few months of the year, but those whose costs fall just below the threshold may never trigger the zero-cost phase at all.
The speed of these annual increases matters because the IRA’s promise was to shield seniors from catastrophic drug costs. If the API pushes the cap upward faster than typical household income growth for retirees, the gap between the original $2,000 promise and actual exposure widens each year. Two years in, the trajectory suggests that the annual adjustment is not a minor technical tweak but a meaningful shift in how much beneficiaries must spend before full protection begins.
CMS documents that confirm the $2,400 figure
The $2,400 threshold for 2027 appears in the CMS Retiree Drug Subsidy announcement for plan years ending in 2027, which lists the Part D benefit parameters including cost thresholds and cost limits. The same figure is referenced in the CY 2027 Medicare Advantage and Part D Rate Announcement fact sheet published by CMS, and the Government Accountability Office has separately documented that rate announcement as a formal federal action.
The chain of adjustments is also well documented. CMS program instructions for 2026 explicitly state that the $2,100 threshold for that year results from applying the API to the original $2,000 cap established for 2025. The same formula produced the $2,400 figure for 2027, though CMS has not published a detailed breakdown of how it calculated the specific percentage increase that bridges the two years. The absence of that calculation makes it difficult for beneficiaries and advocates to anticipate how quickly the cap might climb in later years, especially if drug spending trends or inflation shift.
How the new cap fits into the broader Part D redesign
The out-of-pocket limit is just one piece of a wider set of Part D improvements that CMS is implementing under the IRA. The law phases in lower cost sharing in the catastrophic coverage phase, restructures how plans and manufacturers share liability, and adds new protections such as the ability for beneficiaries to spread their drug costs over the year through a “smoothing” mechanism. These changes are intended to work together so that, even as the cap rises, people with the highest prescription drug needs are not hit with unaffordable bills in a single month.
Still, the cap is the most visible benchmark for many enrollees because it translates directly into a maximum annual exposure. For a beneficiary taking multiple chronic medications, the difference between a $2,100 and a $2,400 ceiling can mean an extra month or more of copayments before reaching the point where drugs become free for the remainder of the year. For lower-income beneficiaries who do not qualify for the full Low-Income Subsidy, that additional spending can compete with rent, utilities and food.
What beneficiaries and plans should watch next
Looking ahead, the key unknown is how quickly the API will move the cap after 2027. The statute allows for annual increases based on growth in Part D costs, which could accelerate if high-priced therapies enter the market or if utilization rises. If that happens, the nominal cap could climb well beyond $2,400 within a few years, gradually diluting the impact of the original $2,000 promise even as the legal guarantee of a cap remains.
For plans and employers that offer retiree coverage, the higher threshold also affects benefit design. As the cap rises, sponsors may revisit formularies, tier structures and supplemental coverage to manage their own financial exposure. Some may choose to wrap around the statutory cap with additional protections, while others may lean more heavily on utilization management tools such as prior authorization and step therapy to keep enrollees from reaching the threshold too quickly.
For beneficiaries, the most immediate step is to pay close attention during annual enrollment periods. Comparing plan premiums, formularies and cost-sharing rules will matter more as the cap moves upward, because the path to that limit can differ significantly from one plan to another even though the statutory threshold is the same. The IRA has locked in the existence of a cap; the emerging story is how much that protection is worth in practice as the number attached to it continues to grow.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
